bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating reiterated by analysts at Maxim Group in a note issued to investors on Monday. They currently have a $170.00 target price on the biotechnology company’s stock, up from their previous target price of $100.00. Maxim Group’s price objective suggests a potential upside of 29.13% from the company’s previous close.
BLUE has been the subject of a number of other research reports. Zacks Investment Research cut bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub cut bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. Morgan Stanley cut bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 target price for the company. in a research report on Monday, October 2nd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $116.91.
bluebird bio (BLUE) opened at 131.65 on Monday. bluebird bio has a 12 month low of $37.05 and a 12 month high of $143.50. The firm’s market capitalization is $6.00 billion. The firm’s 50-day moving average is $123.70 and its 200-day moving average is $101.61.
bluebird bio (NASDAQ:BLUE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm’s revenue for the quarter was up 977.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.59) EPS. On average, equities research analysts expect that bluebird bio will post ($6.85) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) Stock Rating Reaffirmed by Maxim Group” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/11/bluebird-bio-inc-blue-stock-rating-reaffirmed-by-maxim-group.html.
In related news, Director John Maraganore sold 18,868 shares of bluebird bio stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $131.21, for a total value of $2,475,670.28. Following the sale, the director now owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider David Davidson sold 3,000 shares of bluebird bio stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $92.37, for a total value of $277,110.00. Following the completion of the sale, the insider now directly owns 18,977 shares in the company, valued at approximately $1,752,905.49. The disclosure for this sale can be found here. In the last three months, insiders sold 126,879 shares of company stock worth $15,401,808. 3.90% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of BLUE. BlackRock Inc. increased its position in shares of bluebird bio by 44,948.0% during the 1st quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock worth $289,259,000 after purchasing an additional 3,175,124 shares during the last quarter. FMR LLC increased its holdings in shares of bluebird bio by 9.6% during the 2nd quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after acquiring an additional 587,236 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of bluebird bio by 9.9% during the 2nd quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after acquiring an additional 493,072 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of bluebird bio by 10.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after acquiring an additional 343,856 shares during the last quarter. Finally, Voya Investment Management LLC increased its holdings in shares of bluebird bio by 1,251.6% during the 2nd quarter. Voya Investment Management LLC now owns 217,398 shares of the biotechnology company’s stock worth $22,837,000 after acquiring an additional 201,313 shares during the last quarter.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.